PMID- 20201740
OWN - NLM
STAT- MEDLINE
DCOM- 20100603
LR  - 20100305
IS  - 1744-7593 (Electronic)
IS  - 1742-5247 (Linking)
VI  - 7
IP  - 3
DP  - 2010 Mar
TI  - Drug delivery strategies for therapy of visceral leishmaniasis.
PG  - 371-402
LID - 10.1517/17425240903548232 [doi]
AB  - IMPORTANCE OF THE FIELD: Visceral leishmaniasis (VL) is the most overwhelming 
      type of leishmaniasis associated with the poverty of developing countries and 
      usually mortal if untreated. Most of the conventionally used dosage forms offer 
      us the shortcomings of toxic side effects and emergence of drug resistance. 
      Several efforts have been made to overcome the barriers involved in the treatment 
      of VL. Colloidal carriers extensively represent the drug delivery systems (DDSs) 
      for intracellular localization of antileishmanial compounds in macrophage-rich 
      organs such as liver, spleen and bone marrow. These DDSs offer superior 
      therapeutic efficacy over the conventional treatment in terms of site-specific 
      drug delivery with reduced side effects. However, after 35 years of research in 
      the field, AmBisome (Amphotericin B liposome for injection, Astellas Pharma US, 
      Inc.) is the only DDS used against the VL. AREAS COVERED IN THIS REVIEW: A 
      literature search was performed (for drugs and DDSs against VL) on PubMed and 
      through Google. WHAT THE READER WILL GAIN: This review aims to describe the 
      pathophysiology of VL and its current conventional treatment with special 
      reference to DDSs designed against VL. TAKE HOME MESSAGE: On reviewing the 
      conventional drugs and DDSs developed against VL, it is concluded that advances 
      in the field of targeted drug delivery can result in more efficient strategies 
      for the therapy of VL.
FAU - Gupta, Swati
AU  - Gupta S
AD  - Nanomedicine Research Center, Department of Pharmaceutics, ISF College of 
      Pharmacy, Moga (PB), India. swatig25@gmail.com
FAU - Pal, Ajay
AU  - Pal A
FAU - Vyas, Suresh P
AU  - Vyas SP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Expert Opin Drug Deliv
JT  - Expert opinion on drug delivery
JID - 101228421
RN  - 0 (Antiprotozoal Agents)
RN  - 0 (Colloids)
RN  - 0 (Drug Carriers)
SB  - IM
MH  - Antiprotozoal Agents/*administration & dosage/therapeutic use
MH  - Colloids
MH  - *Drug Carriers
MH  - Host-Parasite Interactions
MH  - Humans
MH  - Leishmaniasis, Visceral/*drug therapy
RF  - 268
EDAT- 2010/03/06 06:00
MHDA- 2010/06/04 06:00
CRDT- 2010/03/06 06:00
PHST- 2010/03/06 06:00 [entrez]
PHST- 2010/03/06 06:00 [pubmed]
PHST- 2010/06/04 06:00 [medline]
AID - 10.1517/17425240903548232 [doi]
PST - ppublish
SO  - Expert Opin Drug Deliv. 2010 Mar;7(3):371-402. doi: 10.1517/17425240903548232.